Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Obstetrics and Gynecology
Volume 2013 (2013), Article ID 186230, 3 pages
http://dx.doi.org/10.1155/2013/186230
Case Report

Life-Threatening Complications of Hormonal Contraceptives: A Case History

1Department of Intensive Care, VU Medical Center, Postbus 7057, 1007 MB Amsterdam, The Netherlands
2Department of Internal Medicine, VU Medical Center, Postbus 7057, 1007 MB Amsterdam, The Netherlands
3Department of Gynaecology, VU Medical Center, Postbus 7057, 1007 MB Amsterdam, The Netherlands

Received 17 April 2013; Accepted 8 May 2013

Academic Editors: P. De Franciscis, C. Ficicioglu, S.-Y. Ku, C.-C. Liang, M. A. Osmanagaoglu, and S. Rasmussen

Copyright © 2013 Saheed Khan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Reid, N. Leyland, W. Wolfman et al., “Oral contraceptives and the risk of venous thromboembolism: an update,” International Journal of Gynecology and Obstetrics, vol. 112, no. 3, pp. 252–256, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. C. Hannaford, “Epidemiology of the contraceptive pill and venous thromboembolism,” Thrombosis Research, vol. 127, supplement 3, pp. S30–S34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Rott, “Thrombotic risks of oral contraceptives,” Current Opinion in Obstetrics and Gynecology, vol. 24, pp. 235–240, 2012. View at Publisher · View at Google Scholar
  4. T. G. DeLoughery, “Estrogen and thrombosis: controversies and common sense,” Reviews in Endocrine and Metabolic Disorders, vol. 12, no. 2, pp. 77–84, 2011. View at Publisher · View at Google Scholar
  5. O. Lidegaard, L. H. Nielsen, C. W. Skovlund, F. E. Skjeldestad, and E. Lokkegaard, “Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9,” British Medical Journal, vol. 343, article d6423, 2011. View at Google Scholar
  6. L. P. Shulman, “The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives,” American Journal of Obstetrics & Gynecology, vol. 205, pp. S9–S13, 2011. View at Google Scholar
  7. I. Martinelli, E. Taioli, T. Battaglioli et al., “Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives,” Archives of Internal Medicine, vol. 163, no. 22, pp. 2771–2774, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Lidegaard, I. Milsom, R. T. Geirsson, and F. E. Skjeldestad, “Hormonal contraception and venous thromboembolism,” Acta Obstetricia et Gynecologica Scandinavica, vol. 91, pp. 769–778, 2012. View at Publisher · View at Google Scholar
  9. J. Bourne Rooks, H. W. Ory, K. G. Ishak et al., “Epidemiology of hepatocellular adenoma. The role of oral contraceptive use,” Journal of the American Medical Association, vol. 242, no. 7, pp. 644–648, 1979. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Rebouissou, P. Bioulac-Sage, and J. Zucman-Rossi, “Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma,” Journal of Hepatology, vol. 48, no. 1, pp. 163–170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. C. La Vecchia and A. Tavani, “Female hormones and benign liver tumours,” Digestive and Liver Disease, vol. 38, no. 8, pp. 535–536, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Lizardi-Cervera, L. Cuéllar-Gamboa, and D. Motola-Kuba, “Focal nodular hyperplasia and hepatic adenoma: a review,” Annals of Hepatology, vol. 5, no. 3, pp. 206–211, 2006. View at Google Scholar · View at Scopus
  13. O. T. Terpstra, E. J. van Hasselt, F. W. J. ten Kate, J. S. Lameris, S. W. Schalm, and H. van Urk, “Benign liver tumors and oral contraceptives: diagnosis and treatment,” Nederlands Tijdschrift voor Geneeskunde, vol. 130, no. 15, pp. 685–689, 1986. View at Google Scholar · View at Scopus
  14. R. Veteläinen, D. Erdogan, W. de Graaf et al., “Liver adenomatosis: re-evaluation of aetiology and management,” Liver International, vol. 28, no. 4, pp. 499–508, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Barthelmes and I. S. Tait, “Liver cell adenoma and liver cell adenomatosis,” HPB, vol. 7, no. 3, pp. 186–196, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Erdogan, O. M. van Delden, O. R. C. Busch, D. J. Gouma, and T. M. van Gulik, “Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas,” CardioVascular and Interventional Radiology, vol. 30, no. 6, pp. 1252–1258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. H. M. B. Stoot, E. van der Linden, O. T. Terpstra, and A. F. M. Schaapherder, “Life-saving therapy for haemorrhaging liver adenomas using selective arterial embolization,” British Journal of Surgery, vol. 94, no. 10, pp. 1249–1253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. W. Blayney, T. O'Callaghan, D. P. MacErlean, and T. C. J. O'Connell, “Fatal outcome of an hepatic adenoma following short term oral contraceptive use,” Irish Medical Journal, vol. 70, no. 15, pp. 455–456, 1977. View at Google Scholar · View at Scopus